Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01464996 · ClinicalTrials.gov registry record · NA
Clinical Evaluation Of A New Two-Component Self-Etch Universal Adhesive
A NA study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT01464996 is a NA study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 24 participants.
The verdict
NCT01464996, a NA study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
This randomized clinical trial evaluates the clinical performance of a new two-component self-etch universal adhesive, OptiBond XTR, when applied in non-carious Class V cervical lesions without macromechanical retention (retentive grooves or bevels). The control material is OptiBond FL, a "traditional" etch/prime/bond adhesive with documented clinical performance. Eighty non-carious Class V cervical lesions are divided into two groups to be treated with either OptiBond XTR or OptiBond FL. Both adhesives are applied strictly according to the manufacturer's directions. Herculite Ultra, a nano-hybrid resin-based composite, is used as the restorative material with both adhesives. The restorations will be evaluated at insertion (baseline), 6 months, and 18 months. An optional three-year recall evaluation is also proposed. The investigators hypothesize that both adhesives will have comparable performance.
Interventions
- PROCEDURE Adhesive: OptiBond XTR; Composite: Herculite Ultra
- PROCEDURE Adhesive: OptiBond FL; Composite: Herculite Ultra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-12 |
| Est. Completion | 2014-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01464996
The ClinicalTrials.gov registry entry for NCT01464996 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Adhesive: OptiBond XTR; Composite: Herculite Ultra is the first listed.
NCT01464996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01464996 about?
NCT01464996 is a clinical study titled "Clinical Evaluation Of A New Two-Component Self-Etch Universal Adhesive". This randomized clinical trial evaluates the clinical performance of a new two-component self-etch universal adhesive, OptiBond XTR, when applied in non-carious Class V cervical lesions without macromechanical retention (retentive grooves or bevels). The control material is OptiBond FL, a "tradition...
What is the current status of trial NCT01464996?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2011-12. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01464996?
The interventions under investigation include: Adhesive: OptiBond XTR; Composite: Herculite Ultra (PROCEDURE), Adhesive: OptiBond FL; Composite: Herculite Ultra (PROCEDURE).
Who is sponsoring clinical trial NCT01464996?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.